Lund, Sweden 14 January 2010. BioInvent International AB (publ) (OMXS: BINV) today announced that the company's Board of Directors decided, after the closing of trading at NASDAQ OMX Stockholm on 13 January 2010, to carry out a directed new share issue with deviation from the shareholders' preferential rights, subject to approval at the extraordinary general meeting, of in total 5,434,800 shares in order to raise SEK 150 million before transaction expenses. The subscription price is set to SEK 27.60 per share representing a 0.6 percent discount to the one month volume weighted average closing price prior to the Board of Directors' resolution to issue new shares.

Simultaneously, BioInvent's Board of Directors decided to summon to an extraordinary general meeting 2 February 2010 in order to approve the Board of Directors' resolution to issue new shares.

The release date of the year-end report and the interim report for October-December 2009 has been changed to 28 January 2010.

The directed new share issue strengthens BioInvent's financial position, thus ensuring continued development and value creation in the company's project portfolio. The proceeds will be used to finance the continued development of the company's existing projects as well as to widen and strengthen the preclinical research and the development of new candidate drugs. The directed new share issue also strengthens BioInvent's position in ongoing and future discussions with existing and potential partners, thus giving the company more flexibility in the timing of new partnerships.

The purpose of the resolution to issue new shares with deviation from the shareholders' preferential rights is to widen the long-term industrial and the international institutional ownership in BioInvent. The directed new share issue is subscribed by DnB NOR Asset Management, the Nordic team (1,521,800 shares) and B & E Participation AB (3,913,000 shares). DnB NOR Asset Management is one of largest asset management firms in the Nordic region. B & E Participation AB is owned by Lars Backsell and Thomas Eldered, both with extensive experience from the international pharmaceutical industry through the creation and development of Recip AB and Recipharm AB. The resolution implies an insignificant financial dilution for the existing shareholders compared to the one month volume weighted average closing price.

Svein Mathisen, CEO of BioInvent, commented, "Our project portfolio has made strong progress during 2009. The proceeds from the directed new share issue and the broadening of the shareholder base demonstrate our ambition to further strengthen the company's development as an antibody company", commented Svein Mathisen, CEO of BioInvent."

The Board of Directors' resolution to issue new shares with deviation from the shareholders' preferential rights
The Board of Directors' resolution to issue new shares is subject to approval of the extraordinary general meeting on Tuesday 2 February 2010 16:00 CET in the company's office in Lund, in accordance with the enclosed notice. In total, 5,434,800 shares will be issued and the subscription price is set to SEK 27.60 per share, which means that the new issue will raise SEK 150 million before transaction expenses. The new issue results in an equity dilution of 8.9 percent and the subscription price represents a discount of 0.6 percent compared to the one month volume weighted average closing price and 4.2 percent based on the closing price before the resolution to issue new shares.

Advisors
ABG Sundal Collier acts as financial advisor and Mannheimer Swartling Advokatbyrå acts as legal advisor to BioInvent in connection to the directed new share issue.

-- END --

Notes to Editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based
pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, Daiichi Sankyo, ImmunoGen, Mitsubishi Tanabe, OrbusNeich, UCB and XOMA. More information is available at www.bioinvent.com.

For further information, please contact:

 BioInvent International AB
 Svein Mathisen	
 President & CEO	
 Tel: +46 (0)46-286 85 67	
 Mobile: +46 (0)708-97 82 13	
 E-mail: [email protected]	

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected]

College Hill (media enquiries)
Holly Griffiths, Sue Charles, Benjamyn Tan
Tel: +44 (0)20 7457 2020
Erik Clausen, Kena Hudson (US)
Tel: +1 415-230-5385
E-mail: [email protected]

 BioInvent International AB (publ)	
 Co. reg. No. 556537-7263,		
 Address:  Sölvegatan 41		
 Mailing address: SE-223 70 LUND	
 Tel: +46 (0)46 286 85 50		
 [email protected]		
 www.bioinvent.com		

BioInvent publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on 14 January 2010 at 10.50 a.m. CET.

Important information
This announcement does not contain or constitute an offer to sell or the solicitation of an offer to buy securities in BioInvent International AB.

Extra General Meeting in Bioinvent International AB

The shareholders of BioInvent International AB (publ), reg no 556537-7263, are hereby invited to attend the Extra General Meeting (the "EGM") to be held at 4 p.m., Tuesday February 2, 2010 at Ideon, Sölvegatan 41, Lund, Sweden.

 A.	NOTICE OF ATTENDANCE 

Shareholders who wish to attend the EGM must:

 (i) 	be recorded in the printout of the share register maintained by Euroclear Sweden AB ("Euroclear"), as of Wednesday January 27, 2010;

and

 (ii) 	notify the company of their intention to attend the meeting at address: Sölvegatan 41, SE-223 70 Lund, Sweden, att: Marie Serwe, by telefax 
 +46 46 211 08 06 or by telephone +46 46 286 85 50, or e-mail [email protected] at 4 p.m., Wednesday January 27, 2010 at the latest.

In order to participate in the proceedings at the EGM, shareholders with nominee-registered shares must request their bank or broker to have the shares temporarily owner-registered with Euroclear. Such registration must be made as per Wednesday January 27, 2010 and the bank or broker should therefore be notified in due time before said date.

On giving notice of attendance, the shareholder shall state name, personal identity number/registration number, number of shares held, phone number and, if applicable, the name of the representative. Proxy to act on behalf of a shareholder should be sent together with the notice of attendance. Representative of a legal person shall hand in a copy of a registration certificate or similar papers of authorisation. The company will supply proxy forms upon request from a shareholder.

 B. 	AGENDA 

Proposal for Agenda

 1.	Opening of the Meeting.
 2.	Election of Chairman of the Meeting.
 3.	Preparation and approval of the voting list.
 4.	Election of persons to check the minutes.
 5.	Determination of compliance with the rules of convocation.
 6.	Approval of the Agenda.
 7. 	Approval of the Board of Directors' resolution on a directed new share issue 
 8.	Closing of the Meeting.

Present proposals on the agenda (item 7)

The Board of Directors proposes that the general meeting resolves to approve the Board of Director's resolution on a new share issue of 5,434,800 shares, involving an increase of the company's share capital by SEK 2,717,400, corresponding to an equity dilution of 8.9 percent. The right to subscribe for new shares shall be granted to ABG Sundal Collier AB, on behalf of DnB NOR Asset Management with 1,521,800 shares and on behalf of B & E Participation AB with 3,913,000 shares. The subscription price shall be SEK 27,60 per share to be paid in cash no later than 5 February 2010. The purpose of the new share issue and the reasons for the derogation from the shareholders' preferential rights, are to strengthen the company's financial position and at the same time to broaden the long term industrial and international institutional ownership structure of the company. The principles on which the subscription price is based, are 0,6 percent discount on the one month volume weighted average price before the decision of the Board of Directors and a discount of 4,2 percent based on the closing price paid for the company's share in connection with the resolution to issue new shares.

 C.	DOCUMENTATION

The Board of Directors' complete proposal on new share issue will be held available at the company's premises as from 19 February 2010 and will upon request be sent to shareholders who state their address. The documents will also be available at the website of the company, www.bioinvent.se.

The total number of shares and votes in the company amounts to 55,660,889.

___

Lund in January 2010
The Board of Directors
BIOINVENT INTERNATIONAL AB (PUBL)